Abstract
The effect of tilmicosin on fetal development in pregnant female rats was investigated in this study. Forty pregnant female rats were divided into four groups (each of 10 female rats). Rats in the 1st, 2nd and 3rd groups were received tilmicosin at a dose of 20, 100, 200 mg/kg·b·wt/day orally from the 6th to 15th day of gestation respectively, while the 4th group received 0.5 ml distilled water orally for the same period of gestation and was used as control group. All the pregnant female rats were sacrificed on the 20th day of gestation and their fetuses were subjected to morphological, visceral and skeletal examinations. Tilmicosin at a dose 100, 200 mg/kg·b·wt significantly decreased the number of viable fetuses; the number of resorbed fetuses was increased, and induced retardation in growth of viable fetuses; some skeletal and visceral defects in these fetuses were observed and these effects were dose dependant. It could be concluded that tilmicosin caused some abnormalities and fetal defects, so it is recommended to avoid using pregnancy.
Highlights
Macrolide antibiotics are frequently used for presumed or documented Gram-positive lower and upper respiratory infections, Helicobacter pylori-related peptic ulcer and soft tissue infections
The aim of this study was to investigate the influence of tilmicosin on the fetal development in the organogenesis period in albino rats
Oral administration of tilmicosin in doses (100 and 200 mg/kg∙b∙wt) to female pregnant rats induced significant decrease in the number of viable fetuses/mother when compared with control group without any fetal death
Summary
Macrolide antibiotics are frequently used for presumed or documented Gram-positive lower and upper respiratory infections, Helicobacter pylori-related peptic ulcer and soft tissue infections. For the treatment of chlamydia and other selected infections in pregnancy [1], macrolide antibiotics are the second most frequently used antibacterial class during pregnancy [2] [3]. It has excellent in vitro activity which is reported for Gram-positive bacteria and mycoplasma, and for certain Gram-negative microbes such as Actinobacillus pleuropneumoniae, Pasteurella bemolytica, and Pasteurella multocida [4]. It is approved for treatment of bo-.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
